{"ticker": {"uuid": "b3edcd17-085e-402e-bad7-9741fea7034a", "symbol": "RNXT", "name": "RenovoRx Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RenovoRx, Inc. Net Income (RNXT)", "summary": "RenovoRx, Inc.'s net income was -$11.2M in FY2025, an increase from -$8.8M in FY2024, with the most recent quarter (Q1 FY26) showing a net income of -$3.5M. The article provides detailed annual and quarterly financial figures, including net income, operating income, and revenue, ", "url": "https://mlq.ai/companies/renovorx-inc/net-income/", "source_name": "MLQ.ai", "published_at": "2026-07-09T09:43:27", "published_display": "09 Jul 2026 09:43", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNXT - RenovoRx Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for RenovoRx Inc (RNXT), detailing various financial metrics, performance indicators, and company statistics. It includes data on market capitalization, enterprise value, income, sales, EPS, insider and institutional ownersh", "url": "https://finviz.com/stock?t=RNXT&ta=1&p=d&ty=lf&b=1&page=4", "source_name": "Finviz", "published_at": "2026-07-04T12:40:25", "published_display": "04 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk", "summary": "RenovoRx (RNXT) has received an extended compliance period from Nasdaq until December 28, 2026, to regain the minimum $1.00 bid price requirement, following an initial notice in December 2025. Failure to meet this condition could lead to delisting, though the company retains appe", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RNXT-Q/pressreleases/3116391/renovorx-granted-extended-nasdaq-compliance-period-amid-listing-risk/", "source_name": "The Globe and Mail", "published_at": "2026-07-04T08:12:02", "published_display": "04 Jul 2026 08:12", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Stockholders Approve Directors and Equity Plan", "summary": "RenovoRx stockholders approved the election of seven directors and an amendment to the company's 2021 Omnibus Equity Incentive Plan, adding 2,000,000 shares for equity-based compensation. They also ratified the appointment of Frank, Rimerman + Co. LLP as the independent registere", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RNXT/pressreleases/3087004/renovorx-stockholders-approve-directors-and-equity-plan/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T18:09:46", "published_display": "02 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Receives Nasdaq Delisting Notice: Key Details from Latest 8-K Filing", "summary": "RenovoRx, Inc. (RNXT) has received an extension from Nasdaq until December 28, 2026, to regain compliance with the minimum bid price requirement of $1.00. The company initially had until June 30, 2026, but was granted an additional 180 days. This extension provides temporary reli", "url": "https://www.minichart.com.sg/2026/07/02/renovorx-receives-nasdaq-delisting-notice-key-details-from-latest-8-k-filing/", "source_name": "Minichart", "published_at": "2026-07-02T13:40:38", "published_display": "02 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Received Notice of Noncompliance", "summary": "RenovoRx (RNXT) was notified by Nasdaq on July 1, 2026, that it remains noncompliant with the $1.00 minimum bid price rule. The company has been granted a second 180-day period until December 28, 2026, to regain compliance. Failure to maintain a bid price of at least $1.00 for 10", "url": "https://www.tradingview.com/news/tradingview:5bd8b22a4c193:0-renovorx-received-notice-of-noncompliance/", "source_name": "TradingView", "published_at": "2026-07-02T12:40:38", "published_display": "02 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 23, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq grants RenovoRx (RNXT) new deadline to fix $1 bid price", "summary": "RenovoRx (RNXT) has been granted a second 180-day extension by Nasdaq, until December 28, 2026, to regain compliance with the $1.00 minimum bid price requirement. To meet this, the company's stock must close at or above $1.00 for at least 10 consecutive business days. Failure to ", "url": "https://www.stocktitan.net/sec-filings/RNXT/8-k-renovo-rx-inc-reports-material-event-130faa05dd75.html", "source_name": "Stock Titan", "published_at": "2026-07-01T17:40:38", "published_display": "01 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) investors approve directors, expand equity plan and ratify 2026 auditor", "summary": "RenovoRx, Inc. (RNXT) stockholders have approved the election of all seven director nominees, expanded the 2021 Omnibus Equity Incentive Plan by adding 2,000,000 shares, and ratified Frank, Rimerman + Co. LLP as the independent registered public accounting firm for the year endin", "url": "https://www.stocktitan.net/sec-filings/RNXT/8-k-renovo-rx-inc-reports-material-event-0927726377ae.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:07:32", "published_display": "01 Jul 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides an extensive list of RenovoRx, Inc.'s SEC filings and other corporate documents, including earnings reports, investor presentations, and conference transcripts from 2024 through 2026. These disclosures detail the company's financial performance, operational ", "url": "https://www.tradingview.com/symbols/BOATS-RNXT/documents/", "source_name": "TradingView", "published_at": "2026-07-01T00:09:32", "published_display": "01 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) Edges Higher, Testing Key Resistance at $1.02 - MACD Signal Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQeHgzMWRjV0wtOWo2U1FnY3lRYlNiMDItQUV0a21tdXlieUZ3QnZUb0pEQndIendvSDlpQ0JpMklYX3FIUThPb0lmTHpYWTZVWW5nTGlXcWFHZnJVbWE0QUtERzh6ZHpETHNfenZFbXdnaFNaRXBxdGNqbVVOY3M0emRDQnB3OGcyUG5zR2RLZVB0a09tNnVCVmktUkU4bnc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of RenovoRx Inc (RNXT), noting its current valuation score of 6.02, which ranks it 194 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -2.85, indicating it is significantly bel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-27T04:10:09", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of RenovoRx, Inc. \u2013 NASDAQ:RNXT", "summary": "This article provides financial data for RenovoRx, Inc. (NASDAQ: RNXT), specifically focusing on its \"Price to book forward\" metric. It appears to be a stub or a section of a larger financial information page on TradingView. The page lacks detailed analysis, indicating that it se", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:41:01", "published_display": "27 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNXT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and various financial details for RenovoRx, Inc. (RNXT) stock, including analyst price targets, current stock performance, and historical data. It also summarizes the company's recent earnings, revenue, and other financial metrics, noting its mark", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T03:41:01", "published_display": "27 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of RenovoRx, Inc. \u2013 NASDAQ:RNXT", "summary": "This article provides a brief financial overview for RenovoRx, Inc. (NASDAQ: RNXT) focusing on its enterprise value to revenue forward metric. It appears to be a stub or placeholder from TradingView, indicating specific financial data for the company. The content also includes ex", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:09:30", "published_display": "26 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. Actuals & Estimates (NASDAQ:RNXT)", "summary": "This article provides an overview of RenovoRx, Inc. (NASDAQ:RNXT) stock, including its current price, historical performance, analyst forecasts, and financial metrics. It details the company's market capitalization, earnings, revenue, and EBITDA, along with future earnings report", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:31", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 RenovoRx Inc For: 24 June By Investing.com", "summary": "The article reports on a Form 4 filing for RenovoRx Inc. (RNXT) for June 24, as published by Investing.com. It is a brief announcement without further details within the provided text, indicating a standard regulatory disclosure.", "url": "https://za.investing.com/news/stock-market-news/form-4-renovorx-inc-for-24-june-93CH-4342854", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T22:14:26", "published_display": "25 Jun 2026 22:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of RenovoRx, Inc. \u2013 NASDAQ:RNXT", "summary": "This article focuses on the enterprise value to EBITDA forward for RenovoRx, Inc. (NASDAQ: RNXT). It appears to be a financial data page from TradingView, indicating that the market for RNXT was closed with no trades at the time of access. The primary content is a statement about", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:33:31", "published_display": "25 Jun 2026 20:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) Holds Near Support as Micro-Cap Biotech Shows Modest Uptick - Liquidity Order Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPR2w3eENqd29WbmZNOWVKTHlTVnREOTh5NjIxQWpLVFRfTWFnRFN2WTgzaUFxdlIyWDRFTHUxRmdpMzFHejN2VHZGOWV2enRiaGZfUUNyNFU0eTR0R0E2QU5jek01Nm4wRWlWQS1pclowMzlvQk5aTkU2SUIzTUNEQkdPZWxxcUNCZ2puN0lQbFRhZ0JlNGFVN3VMQTRuZTVDTkVTS1htaE5sclJKOW1hdDUyQ1F3Uk5u?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) director reorganizes indirect share holdings via trust", "summary": "RenovoRx director Una S. Ryan has restructured her indirect shareholdings in the company through The Una S. Ryan Revocable Trust. This involved 97,165 shares from distributions by Astria Fund and Golden Seeds Venture Fund GP, where Ryan is a non-managing member. These \"other\" tra", "url": "https://www.stocktitan.net/sec-filings/RNXT/form-4-renovo-rx-inc-insider-trading-activity-87a4836dad84.html", "source_name": "Stock Titan", "published_at": "2026-06-24T21:10:08", "published_display": "24 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNXT: Strong commercial growth and clinical data position the therapy for major impact in cancer care", "summary": "The article highlights RenovoRx, Inc. (RNXT) for its novel cancer therapy device, which shows strong commercial growth, rapid adoption in top medical centers, and positive interim clinical data demonstrating improved survival and reduced toxicity. The company expects to reach bre", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3640558:0-rnxt-strong-commercial-growth-and-clinical-data-position-the-therapy-for-major-impact-in-cancer-care/", "source_name": "TradingView", "published_at": "2026-06-23T17:40:49", "published_display": "23 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. (RNXT) reports Q1 loss, tops revenue estimates", "summary": "This article focuses on RenovoRx, Inc. (RNXT)'s Q1 financial results. The company reported a loss per share of $-0.26, which is higher than the analyst estimate of $-0.39. Additionally, RenovoRx surpassed revenue expectations, bringing in $0.78 million compared to the estimated $", "url": "https://www.msn.com/en-us/money/other/renovorx-inc-rnxt-reports-q1-loss-tops-revenue-estimates/ar-AA23de1N?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-06-22T10:11:00", "published_display": "22 Jun 2026 10:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses RenovoRx Inc (RNXT)'s revenue breakdown, specifically addressing business segments, regional revenue, and profit contribution. However, the critical financial data for these categories has not yet been disclosed by the company, rendering the sections current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T04:09:28", "published_display": "19 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of RenovoRx Inc (RNXT) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no record of stock splits. The piece presents current stock data includ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T03:09:28", "published_display": "19 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of RenovoRx Inc (RNXT), including major shareholders and institutional holdings. It lists key individual and institutional investors, their proportion of shares, and changes in their holdings over time. The data provides insight into", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T00:40:18", "published_display": "19 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Institutional Confidence", "summary": "RenovoRx Inc (RNXT) has an institutional shareholding score of 3.00, placing it 132nd out of 203 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 20.02%, showing a slight quarter-over-quarter decrease. James Simons is identified as the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T00:39:09", "published_display": "19 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of RenovoRx Inc (RNXT), focusing on its price momentum, support and resistance levels, and key indicators like MACD, RSI, and moving averages. As of June 18, 2026, the stock's price momentum score is 7.09, suggesting suitability for rang", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/technical", "source_name": "TradingKey", "published_at": "2026-06-18T12:10:21", "published_display": "18 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "RenovoRx Inc (RNXT) has an earnings forecast score of 8.00, placing it 66th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $3.50, with a high of $12.50 and a low of $3.00. Based on ratings from four analysts, most recommend a \"Buy\" t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T19:19:37", "published_display": "17 Jun 2026 19:19", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer", "summary": "RenovoRx announced the publication of a peer-reviewed case study from Moffitt Cancer Center in Radiology Case Reports. The study highlights the successful intra-arterial delivery of gemcitabine via RenovoCath in a patient with locally advanced pancreatic cancer, showcasing a new ", "url": "https://investingnews.com/renovorx-highlights-peer-reviewed-publication-supporting-intra-arterial-gemcitabine-delivery-via-tamp-in-locally-advanced-pancreatic-cancer/", "source_name": "Investing News Network", "published_at": "2026-06-11T18:41:15", "published_display": "11 Jun 2026 18:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP\u2122 in Locally Advanced Pancreatic Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-highlights-peer-reviewed-publication-123000403.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:30:00+00:00", "published_display": "11 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-ceo-shaun-bagai-present-123000096.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:30:00+00:00", "published_display": "04 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc. (RNXT) Q1 2026 Earnings: Loss per share misses estimates as stock declines - EBITDA Estimate Trend", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNd29TLUV1N1g2d3hyb1owbVF4eS1wb21YM2p4UDV1OVAyMmI1b0xyeE55WTUtTFdzRjJBQ1FPSjhSZW1iUXdfZGoxWm5yVkhtV0tEZXFISUg0MjJUcDRadnFORmR3LWpTNXBGeHhoaXVPUGUtdkp1TDh5S1ZLeVBwaE5xdkhCVDdGbGJDWUVuSnRJOU5jSzZ5RDdJSHVmWW5CUkdxOFVha2xES09qOEdhRDlWbW5wd1ZhX1BtVGFpOA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-announces-fda-orphan-drug-123000265.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:30:00+00:00", "published_display": "28 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx receives FDA orphan drug designation for oxaliplatin By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPN05nMmU4Rk5ESkJUQXhvYTBiOUdQTm9GWGtVQmdPVklMN2dVT1QwM1hPT21ma3dUVXZSM1RFZG5KazNBN3ZERDA4c3paNm81Y0ZlRTRBbGxpdVVWNEJPLXpBM293QTdBOW1lQnVWSTAzdUdrWmJYaXJ5akpuMkwxb2hvMDVQQmY1QUxndlRiR3dKaG9Md0d4UXBsOHlKTHF4TXhzM3RjRS0zZmNMS0o3dk5hUmEzbkE2czk0ejI0SQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP\u2122 Platform Presented at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-announces-promising-pharmacokinetic-data-123000026.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T12:30:00+00:00", "published_display": "26 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/92d6a82f-9af0-304e-95b4-c822cf6050a9/renovorx-%28rnxt%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-19T13:00:04+00:00", "published_display": "19 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-present-alliance-global-partners-123000208.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T12:30:00+00:00", "published_display": "19 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx to highlight record RenovoCath revenue, pancreatic cancer trial timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQN1kzM0txcjlrNklOQ0U3NWdkRERlUUN3ME8wWnVJWTJkNC0xLTM2OE5IMDRTR19PVlhSZWxjRlJxb29IRjFsemR1UlR3YnVKQU13cThEZldXNC1hSFU5RlIxU0gydGdiLXRCcS1oeUJ3c1FXb2ZsNnZ5RGk5THpGNlFYNEdzWmEtNG1uNVllMkhlSjFBOU1odVJsZkpMZENqS0VjZEMzVmF3SHoycTdrM3lrMGs5dXpXQzhSb2JmNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/de0053bb-5a18-363e-bae3-fd2153cff91c/renovorx%2C-inc.-q1-2026.html", "source_name": "Moby", "published_at": "2026-05-15T12:30:00+00:00", "published_display": "15 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-inc-rnxt-q1-2026-050158083.html", "source_name": "GuruFocus.com", "published_at": "2026-05-15T05:01:58+00:00", "published_display": "15 May 2026 05:01", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: RenovoRx Q1 2026 revenue beats forecast, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPQWROZFJ1dE9jOUNBSGY4dFVsZDFqX2NHRGRRcnFZX0swSWhUNWZScWszMWpZdjdiSGJ4M1VpbEtfSkRnTFZJMnBCdlhoWVNhVExQQnhhZGlmMkhScGRuREJkUHJDc19jR2ZLbW5ubUtvRXJCbzJmTkxwdG9JTXJkcDBxWVRuNjJXTmFpTW9EWEp0Q3ZQQ1RWVGNBaFJLcXJtTHl3Nm5Ba2ZYek54bmd4WFB3VmpibmRnOXZZUWdwZlEwNUdWZEc5YzVIaG4?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx earnings missed, revenue topped estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOLXdVUGxDNVZjdnp4QjJqUzhPMkF3bW41Z0FxYnNtbS1zZGdmNEdaZ2lBdVlycUFnMFpYeElxdFBBcmlkME82VVBKZE1VYjNoY21lbEc4VWlodlV6aFNlVHpMUUtpWlBaZ1RyaWl4eXZOVm14bFB1THVpZmRVUU9DQURHbUhlb0NqcFlUdU1EZE16Yk83TVBSMlhzVWlsZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQV09sb3hnX2loQURkU2VpLVJubGMyR1Q5ZWZmcy1pdW1rTmxDajRuRE5FSGZEbXF1T0lPWDg1V0czVEV3TjlvNUgwZVVQT0xmbVpWTUx2WE1Qc0pRQlRjNmNNTkJOV2dKWktQODJBSnczN3d3SWFBNTg5bmp4alFFWXFMOUhkZEhheHFMSFN3cFB6UGpTZC1PQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jones Trading initiates coverage on RenovoRx stock with Buy rating By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNOWlRTDc5UF9vNXFOaHZOSjRBWVpuZDh2VUpYNWFhSEVzd0hOTUpieVZ3SVlxQThrbm5PXzF3MmxKbnh5SW01X3loUTR3QVBlY0IwTHFwdUg3MU9QOHlNN2hXSk1vYUhwMTBnZXpkY2ZHYVRybjk1Y3ZUY3BMWEtxV2hFVDY3U0lnZFJ3MWxYTE82a1lvYnZvNFpVRC1mbmVqWndnNnA3d2hPenYzQU5GdFpvSEcxbWphTkxTbURhOHZCdVhxdHBreGkzODI4RjdrbE9Z?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. (NASDAQ:RNXT) Is Expected To Breakeven In The Near Future", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPb1dVN1RxQ3NYMENBZmE0cDBfem9wT0tEVkxwWFdxeE5Ja25zY3pZRzJQc3VtZ3dpWWZWY3Q2SVFaNXZxcjZLNFZGSUhwYUIwQjY5WFJvZWN4aHRwdlZ3NW80QlVxbzZ0dnBmdGVoQ2VzRXg5c1RVTGJZY0ZtckE0VE8tSWlsQVQ2bHZmV1FWYk9RV0VnN0dUS0oteGRpZTF6cEpHZ01BRXRDbDNES0FQSmRuQ0syVkhuMFZPTU5lSnVwLWpzcmtRSzZCME1nN3c0VHc?oc=5", "source_name": "TradingView", "published_at": "2026-01-02T08:00:00+00:00", "published_display": "02 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-16T07:00:00+00:00", "published_display": "16 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE5EUEtQV0NRTVdpbGNYSm5LM0lvejR6UmF1aGUxVjVUMHNpYmNFQ3JLbmZTS3NDb1pQVWpucGhUMnZfVTRScTUzWWN2bXZYVXN5cXdCZXNiZ1E4NzFldGdPREFGdEZRQTJ2?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-10T05:22:52+00:00", "published_display": "10 Jul 2025 05:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Closes $6.1 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbU9CZUF2dU03V1BpNXpEUW56M2lpQXliSnJWUm9wZm5SYnpia0x6NUZ6cXBoRklxZjVzZUc1M1g5c1d2Q05JNHhqQ1BuY20yT2gwamJCVUEtT19FcmRyYWliMHp2eERnM0M0YU5oeUZjYXNsWU9pLWpqR1dpQ1o5UnFZSnlnUEFvVjUtOXppQXo5Zll5YkFrc2VUM2ZQNS11WDhOb2cwcms?oc=5", "source_name": "Business Wire", "published_at": "2024-01-29T08:00:00+00:00", "published_display": "29 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for RenovoRx (RNXT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1lLU9GQXpmeFRBcE5FZ0gzQk5Hb2tObk56aHdyZ29WQzZSM2ZXS3d2eVhNNi1QTnJqZW5MeHhVLUdGSFJycWFCRV9haUVnWi1RaGJjX01lLW9VUERLSmduaUszaFktd3BSZlQ4WEFTdXlzaXRybGd5NA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-15T12:24:37+00:00", "published_display": "15 Aug 2022 12:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy RenovoRx (RNXT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5ZSlEzY0F4QVdtU0xpRWRnRDh2allnZ1psZC1YcVpCWEl1bEl2NkZ6aW54TVFUbUF3OWUtLTFLenBCSDdLcjV4LVBHNnYxbVRPNXRrUkVCdlQtQ1ZZalZqNHN0Y09Nc2ZBUGVqcw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-11-22T18:34:54+00:00", "published_display": "22 Nov 2021 18:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Renovorx (RNXT) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5lSFM0eVpxN0kycDZRNUMtbHYyazViSG1XLUdxdkI2WDhTR0VGQnc4OS14dUUyOGNET3l4Y0djSVhTbURaLUlGT21kM0NwZw?oc=5", "source_name": "Stock Titan", "published_at": "2021-09-07T10:04:02+00:00", "published_display": "07 Sep 2021 10:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "RenovoRx, Inc. Net Income (RNXT)", "summary": "RenovoRx, Inc.'s net income was -$11.2M in FY2025, an increase from -$8.8M in FY2024, with the most recent quarter (Q1 FY26) showing a net income of -$3.5M. The article provides detailed annual and quarterly financial figures, including net income, operating income, and revenue, ", "url": "https://mlq.ai/companies/renovorx-inc/net-income/", "source_name": "MLQ.ai", "published_at": "2026-07-09T09:43:27", "published_display": "09 Jul 2026 09:43", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNXT - RenovoRx Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for RenovoRx Inc (RNXT), detailing various financial metrics, performance indicators, and company statistics. It includes data on market capitalization, enterprise value, income, sales, EPS, insider and institutional ownersh", "url": "https://finviz.com/stock?t=RNXT&ta=1&p=d&ty=lf&b=1&page=4", "source_name": "Finviz", "published_at": "2026-07-04T12:40:25", "published_display": "04 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk", "summary": "RenovoRx (RNXT) has received an extended compliance period from Nasdaq until December 28, 2026, to regain the minimum $1.00 bid price requirement, following an initial notice in December 2025. Failure to meet this condition could lead to delisting, though the company retains appe", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RNXT-Q/pressreleases/3116391/renovorx-granted-extended-nasdaq-compliance-period-amid-listing-risk/", "source_name": "The Globe and Mail", "published_at": "2026-07-04T08:12:02", "published_display": "04 Jul 2026 08:12", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Stockholders Approve Directors and Equity Plan", "summary": "RenovoRx stockholders approved the election of seven directors and an amendment to the company's 2021 Omnibus Equity Incentive Plan, adding 2,000,000 shares for equity-based compensation. They also ratified the appointment of Frank, Rimerman + Co. LLP as the independent registere", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RNXT/pressreleases/3087004/renovorx-stockholders-approve-directors-and-equity-plan/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T18:09:46", "published_display": "02 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Receives Nasdaq Delisting Notice: Key Details from Latest 8-K Filing", "summary": "RenovoRx, Inc. (RNXT) has received an extension from Nasdaq until December 28, 2026, to regain compliance with the minimum bid price requirement of $1.00. The company initially had until June 30, 2026, but was granted an additional 180 days. This extension provides temporary reli", "url": "https://www.minichart.com.sg/2026/07/02/renovorx-receives-nasdaq-delisting-notice-key-details-from-latest-8-k-filing/", "source_name": "Minichart", "published_at": "2026-07-02T13:40:38", "published_display": "02 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Received Notice of Noncompliance", "summary": "RenovoRx (RNXT) was notified by Nasdaq on July 1, 2026, that it remains noncompliant with the $1.00 minimum bid price rule. The company has been granted a second 180-day period until December 28, 2026, to regain compliance. Failure to maintain a bid price of at least $1.00 for 10", "url": "https://www.tradingview.com/news/tradingview:5bd8b22a4c193:0-renovorx-received-notice-of-noncompliance/", "source_name": "TradingView", "published_at": "2026-07-02T12:40:38", "published_display": "02 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 23, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq grants RenovoRx (RNXT) new deadline to fix $1 bid price", "summary": "RenovoRx (RNXT) has been granted a second 180-day extension by Nasdaq, until December 28, 2026, to regain compliance with the $1.00 minimum bid price requirement. To meet this, the company's stock must close at or above $1.00 for at least 10 consecutive business days. Failure to ", "url": "https://www.stocktitan.net/sec-filings/RNXT/8-k-renovo-rx-inc-reports-material-event-130faa05dd75.html", "source_name": "Stock Titan", "published_at": "2026-07-01T17:40:38", "published_display": "01 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) investors approve directors, expand equity plan and ratify 2026 auditor", "summary": "RenovoRx, Inc. (RNXT) stockholders have approved the election of all seven director nominees, expanded the 2021 Omnibus Equity Incentive Plan by adding 2,000,000 shares, and ratified Frank, Rimerman + Co. LLP as the independent registered public accounting firm for the year endin", "url": "https://www.stocktitan.net/sec-filings/RNXT/8-k-renovo-rx-inc-reports-material-event-0927726377ae.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:07:32", "published_display": "01 Jul 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides an extensive list of RenovoRx, Inc.'s SEC filings and other corporate documents, including earnings reports, investor presentations, and conference transcripts from 2024 through 2026. These disclosures detail the company's financial performance, operational ", "url": "https://www.tradingview.com/symbols/BOATS-RNXT/documents/", "source_name": "TradingView", "published_at": "2026-07-01T00:09:32", "published_display": "01 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) Edges Higher, Testing Key Resistance at $1.02 - MACD Signal Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQeHgzMWRjV0wtOWo2U1FnY3lRYlNiMDItQUV0a21tdXlieUZ3QnZUb0pEQndIendvSDlpQ0JpMklYX3FIUThPb0lmTHpYWTZVWW5nTGlXcWFHZnJVbWE0QUtERzh6ZHpETHNfenZFbXdnaFNaRXBxdGNqbVVOY3M0emRDQnB3OGcyUG5zR2RLZVB0a09tNnVCVmktUkU4bnc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of RenovoRx Inc (RNXT), noting its current valuation score of 6.02, which ranks it 194 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -2.85, indicating it is significantly bel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-27T04:10:09", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of RenovoRx, Inc. \u2013 NASDAQ:RNXT", "summary": "This article provides financial data for RenovoRx, Inc. (NASDAQ: RNXT), specifically focusing on its \"Price to book forward\" metric. It appears to be a stub or a section of a larger financial information page on TradingView. The page lacks detailed analysis, indicating that it se", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:41:01", "published_display": "27 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNXT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and various financial details for RenovoRx, Inc. (RNXT) stock, including analyst price targets, current stock performance, and historical data. It also summarizes the company's recent earnings, revenue, and other financial metrics, noting its mark", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T03:41:01", "published_display": "27 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of RenovoRx, Inc. \u2013 NASDAQ:RNXT", "summary": "This article provides a brief financial overview for RenovoRx, Inc. (NASDAQ: RNXT) focusing on its enterprise value to revenue forward metric. It appears to be a stub or placeholder from TradingView, indicating specific financial data for the company. The content also includes ex", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:09:30", "published_display": "26 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. Actuals & Estimates (NASDAQ:RNXT)", "summary": "This article provides an overview of RenovoRx, Inc. (NASDAQ:RNXT) stock, including its current price, historical performance, analyst forecasts, and financial metrics. It details the company's market capitalization, earnings, revenue, and EBITDA, along with future earnings report", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:31", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 RenovoRx Inc For: 24 June By Investing.com", "summary": "The article reports on a Form 4 filing for RenovoRx Inc. (RNXT) for June 24, as published by Investing.com. It is a brief announcement without further details within the provided text, indicating a standard regulatory disclosure.", "url": "https://za.investing.com/news/stock-market-news/form-4-renovorx-inc-for-24-june-93CH-4342854", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T22:14:26", "published_display": "25 Jun 2026 22:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of RenovoRx, Inc. \u2013 NASDAQ:RNXT", "summary": "This article focuses on the enterprise value to EBITDA forward for RenovoRx, Inc. (NASDAQ: RNXT). It appears to be a financial data page from TradingView, indicating that the market for RNXT was closed with no trades at the time of access. The primary content is a statement about", "url": "https://www.tradingview.com/symbols/NASDAQ-RNXT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:33:31", "published_display": "25 Jun 2026 20:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) Holds Near Support as Micro-Cap Biotech Shows Modest Uptick - Liquidity Order Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPR2w3eENqd29WbmZNOWVKTHlTVnREOTh5NjIxQWpLVFRfTWFnRFN2WTgzaUFxdlIyWDRFTHUxRmdpMzFHejN2VHZGOWV2enRiaGZfUUNyNFU0eTR0R0E2QU5jek01Nm4wRWlWQS1pclowMzlvQk5aTkU2SUIzTUNEQkdPZWxxcUNCZ2puN0lQbFRhZ0JlNGFVN3VMQTRuZTVDTkVTS1htaE5sclJKOW1hdDUyQ1F3Uk5u?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) director reorganizes indirect share holdings via trust", "summary": "RenovoRx director Una S. Ryan has restructured her indirect shareholdings in the company through The Una S. Ryan Revocable Trust. This involved 97,165 shares from distributions by Astria Fund and Golden Seeds Venture Fund GP, where Ryan is a non-managing member. These \"other\" tra", "url": "https://www.stocktitan.net/sec-filings/RNXT/form-4-renovo-rx-inc-insider-trading-activity-87a4836dad84.html", "source_name": "Stock Titan", "published_at": "2026-06-24T21:10:08", "published_display": "24 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNXT: Strong commercial growth and clinical data position the therapy for major impact in cancer care", "summary": "The article highlights RenovoRx, Inc. (RNXT) for its novel cancer therapy device, which shows strong commercial growth, rapid adoption in top medical centers, and positive interim clinical data demonstrating improved survival and reduced toxicity. The company expects to reach bre", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3640558:0-rnxt-strong-commercial-growth-and-clinical-data-position-the-therapy-for-major-impact-in-cancer-care/", "source_name": "TradingView", "published_at": "2026-06-23T17:40:49", "published_display": "23 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. (RNXT) reports Q1 loss, tops revenue estimates", "summary": "This article focuses on RenovoRx, Inc. (RNXT)'s Q1 financial results. The company reported a loss per share of $-0.26, which is higher than the analyst estimate of $-0.39. Additionally, RenovoRx surpassed revenue expectations, bringing in $0.78 million compared to the estimated $", "url": "https://www.msn.com/en-us/money/other/renovorx-inc-rnxt-reports-q1-loss-tops-revenue-estimates/ar-AA23de1N?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-06-22T10:11:00", "published_display": "22 Jun 2026 10:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses RenovoRx Inc (RNXT)'s revenue breakdown, specifically addressing business segments, regional revenue, and profit contribution. However, the critical financial data for these categories has not yet been disclosed by the company, rendering the sections current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T04:09:28", "published_display": "19 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of RenovoRx Inc (RNXT) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no record of stock splits. The piece presents current stock data includ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T03:09:28", "published_display": "19 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of RenovoRx Inc (RNXT), including major shareholders and institutional holdings. It lists key individual and institutional investors, their proportion of shares, and changes in their holdings over time. The data provides insight into", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T00:40:18", "published_display": "19 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Institutional Confidence", "summary": "RenovoRx Inc (RNXT) has an institutional shareholding score of 3.00, placing it 132nd out of 203 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 20.02%, showing a slight quarter-over-quarter decrease. James Simons is identified as the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T00:39:09", "published_display": "19 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of RenovoRx Inc (RNXT), focusing on its price momentum, support and resistance levels, and key indicators like MACD, RSI, and moving averages. As of June 18, 2026, the stock's price momentum score is 7.09, suggesting suitability for rang", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/technical", "source_name": "TradingKey", "published_at": "2026-06-18T12:10:21", "published_display": "18 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "RenovoRx Inc (RNXT) has an earnings forecast score of 8.00, placing it 66th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $3.50, with a high of $12.50 and a low of $3.00. Based on ratings from four analysts, most recommend a \"Buy\" t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnxt/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T19:19:37", "published_display": "17 Jun 2026 19:19", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer", "summary": "RenovoRx announced the publication of a peer-reviewed case study from Moffitt Cancer Center in Radiology Case Reports. The study highlights the successful intra-arterial delivery of gemcitabine via RenovoCath in a patient with locally advanced pancreatic cancer, showcasing a new ", "url": "https://investingnews.com/renovorx-highlights-peer-reviewed-publication-supporting-intra-arterial-gemcitabine-delivery-via-tamp-in-locally-advanced-pancreatic-cancer/", "source_name": "Investing News Network", "published_at": "2026-06-11T18:41:15", "published_display": "11 Jun 2026 18:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP\u2122 in Locally Advanced Pancreatic Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-highlights-peer-reviewed-publication-123000403.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:30:00+00:00", "published_display": "11 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-ceo-shaun-bagai-present-123000096.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:30:00+00:00", "published_display": "04 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc. (RNXT) Q1 2026 Earnings: Loss per share misses estimates as stock declines - EBITDA Estimate Trend", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNd29TLUV1N1g2d3hyb1owbVF4eS1wb21YM2p4UDV1OVAyMmI1b0xyeE55WTUtTFdzRjJBQ1FPSjhSZW1iUXdfZGoxWm5yVkhtV0tEZXFISUg0MjJUcDRadnFORmR3LWpTNXBGeHhoaXVPUGUtdkp1TDh5S1ZLeVBwaE5xdkhCVDdGbGJDWUVuSnRJOU5jSzZ5RDdJSHVmWW5CUkdxOFVha2xES09qOEdhRDlWbW5wd1ZhX1BtVGFpOA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-announces-fda-orphan-drug-123000265.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:30:00+00:00", "published_display": "28 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx receives FDA orphan drug designation for oxaliplatin By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPN05nMmU4Rk5ESkJUQXhvYTBiOUdQTm9GWGtVQmdPVklMN2dVT1QwM1hPT21ma3dUVXZSM1RFZG5KazNBN3ZERDA4c3paNm81Y0ZlRTRBbGxpdVVWNEJPLXpBM293QTdBOW1lQnVWSTAzdUdrWmJYaXJ5akpuMkwxb2hvMDVQQmY1QUxndlRiR3dKaG9Md0d4UXBsOHlKTHF4TXhzM3RjRS0zZmNMS0o3dk5hUmEzbkE2czk0ejI0SQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP\u2122 Platform Presented at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-announces-promising-pharmacokinetic-data-123000026.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T12:30:00+00:00", "published_display": "26 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/92d6a82f-9af0-304e-95b4-c822cf6050a9/renovorx-%28rnxt%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-19T13:00:04+00:00", "published_display": "19 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-present-alliance-global-partners-123000208.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T12:30:00+00:00", "published_display": "19 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx to highlight record RenovoCath revenue, pancreatic cancer trial timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQN1kzM0txcjlrNklOQ0U3NWdkRERlUUN3ME8wWnVJWTJkNC0xLTM2OE5IMDRTR19PVlhSZWxjRlJxb29IRjFsemR1UlR3YnVKQU13cThEZldXNC1hSFU5RlIxU0gydGdiLXRCcS1oeUJ3c1FXb2ZsNnZ5RGk5THpGNlFYNEdzWmEtNG1uNVllMkhlSjFBOU1odVJsZkpMZENqS0VjZEMzVmF3SHoycTdrM3lrMGs5dXpXQzhSb2JmNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/de0053bb-5a18-363e-bae3-fd2153cff91c/renovorx%2C-inc.-q1-2026.html", "source_name": "Moby", "published_at": "2026-05-15T12:30:00+00:00", "published_display": "15 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/renovorx-inc-rnxt-q1-2026-050158083.html", "source_name": "GuruFocus.com", "published_at": "2026-05-15T05:01:58+00:00", "published_display": "15 May 2026 05:01", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: RenovoRx Q1 2026 revenue beats forecast, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPQWROZFJ1dE9jOUNBSGY4dFVsZDFqX2NHRGRRcnFZX0swSWhUNWZScWszMWpZdjdiSGJ4M1VpbEtfSkRnTFZJMnBCdlhoWVNhVExQQnhhZGlmMkhScGRuREJkUHJDc19jR2ZLbW5ubUtvRXJCbzJmTkxwdG9JTXJkcDBxWVRuNjJXTmFpTW9EWEp0Q3ZQQ1RWVGNBaFJLcXJtTHl3Nm5Ba2ZYek54bmd4WFB3VmpibmRnOXZZUWdwZlEwNUdWZEc5YzVIaG4?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx earnings missed, revenue topped estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOLXdVUGxDNVZjdnp4QjJqUzhPMkF3bW41Z0FxYnNtbS1zZGdmNEdaZ2lBdVlycUFnMFpYeElxdFBBcmlkME82VVBKZE1VYjNoY21lbEc4VWlodlV6aFNlVHpMUUtpWlBaZ1RyaWl4eXZOVm14bFB1THVpZmRVUU9DQURHbUhlb0NqcFlUdU1EZE16Yk83TVBSMlhzVWlsZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQV09sb3hnX2loQURkU2VpLVJubGMyR1Q5ZWZmcy1pdW1rTmxDajRuRE5FSGZEbXF1T0lPWDg1V0czVEV3TjlvNUgwZVVQT0xmbVpWTUx2WE1Qc0pRQlRjNmNNTkJOV2dKWktQODJBSnczN3d3SWFBNTg5bmp4alFFWXFMOUhkZEhheHFMSFN3cFB6UGpTZC1PQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jones Trading initiates coverage on RenovoRx stock with Buy rating By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNOWlRTDc5UF9vNXFOaHZOSjRBWVpuZDh2VUpYNWFhSEVzd0hOTUpieVZ3SVlxQThrbm5PXzF3MmxKbnh5SW01X3loUTR3QVBlY0IwTHFwdUg3MU9QOHlNN2hXSk1vYUhwMTBnZXpkY2ZHYVRybjk1Y3ZUY3BMWEtxV2hFVDY3U0lnZFJ3MWxYTE82a1lvYnZvNFpVRC1mbmVqWndnNnA3d2hPenYzQU5GdFpvSEcxbWphTkxTbURhOHZCdVhxdHBreGkzODI4RjdrbE9Z?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx, Inc. (NASDAQ:RNXT) Is Expected To Breakeven In The Near Future", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPb1dVN1RxQ3NYMENBZmE0cDBfem9wT0tEVkxwWFdxeE5Ja25zY3pZRzJQc3VtZ3dpWWZWY3Q2SVFaNXZxcjZLNFZGSUhwYUIwQjY5WFJvZWN4aHRwdlZ3NW80QlVxbzZ0dnBmdGVoQ2VzRXg5c1RVTGJZY0ZtckE0VE8tSWlsQVQ2bHZmV1FWYk9RV0VnN0dUS0oteGRpZTF6cEpHZ01BRXRDbDNES0FQSmRuQ0syVkhuMFZPTU5lSnVwLWpzcmtRSzZCME1nN3c0VHc?oc=5", "source_name": "TradingView", "published_at": "2026-01-02T08:00:00+00:00", "published_display": "02 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-16T07:00:00+00:00", "published_display": "16 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx (RNXT) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE5EUEtQV0NRTVdpbGNYSm5LM0lvejR6UmF1aGUxVjVUMHNpYmNFQ3JLbmZTS3NDb1pQVWpucGhUMnZfVTRScTUzWWN2bXZYVXN5cXdCZXNiZ1E4NzFldGdPREFGdEZRQTJ2?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-10T05:22:52+00:00", "published_display": "10 Jul 2025 05:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RenovoRx Closes $6.1 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbU9CZUF2dU03V1BpNXpEUW56M2lpQXliSnJWUm9wZm5SYnpia0x6NUZ6cXBoRklxZjVzZUc1M1g5c1d2Q05JNHhqQ1BuY20yT2gwamJCVUEtT19FcmRyYWliMHp2eERnM0M0YU5oeUZjYXNsWU9pLWpqR1dpQ1o5UnFZSnlnUEFvVjUtOXppQXo5Zll5YkFrc2VUM2ZQNS11WDhOb2cwcms?oc=5", "source_name": "Business Wire", "published_at": "2024-01-29T08:00:00+00:00", "published_display": "29 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for RenovoRx (RNXT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1lLU9GQXpmeFRBcE5FZ0gzQk5Hb2tObk56aHdyZ29WQzZSM2ZXS3d2eVhNNi1QTnJqZW5MeHhVLUdGSFJycWFCRV9haUVnWi1RaGJjX01lLW9VUERLSmduaUszaFktd3BSZlQ4WEFTdXlzaXRybGd5NA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-15T12:24:37+00:00", "published_display": "15 Aug 2022 12:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy RenovoRx (RNXT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5ZSlEzY0F4QVdtU0xpRWRnRDh2allnZ1psZC1YcVpCWEl1bEl2NkZ6aW54TVFUbUF3OWUtLTFLenBCSDdLcjV4LVBHNnYxbVRPNXRrUkVCdlQtQ1ZZalZqNHN0Y09Nc2ZBUGVqcw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-11-22T18:34:54+00:00", "published_display": "22 Nov 2021 18:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Renovorx (RNXT) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5lSFM0eVpxN0kycDZRNUMtbHYyazViSG1XLUdxdkI2WDhTR0VGQnc4OS14dUUyOGNET3l4Y0djSVhTbURaLUlGT21kM0NwZw?oc=5", "source_name": "Stock Titan", "published_at": "2021-09-07T10:04:02+00:00", "published_display": "07 Sep 2021 10:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 61, "sentiment_summary": {"positive": 13, "negative": 10, "neutral": 38, "score": 50, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 13.06, "count": 26}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 0.87, "latest_week": "2026-07-17", "one_week_move": -7.0, "four_week_move": -5.9, "twelve_week_move": 1.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.1313, "market_dynamics_buy_signal": false, "relative_strength": -22.012823, "fair_value_gap": -24.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.1253, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.0% over one week, -5.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "dars.gov.et", "count": 3}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 26}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.0% over one week, -5.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "RenovoRx, Inc. Net Income (RNXT)"}], "updated_at": "2026-07-23T06:09:10.432660+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}